Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ:ITCI) received mixed analyst ratings with 2 bullish, 5 somewhat bullish, and 1 indifferent. The average 12-month price target is $81.75, up from $75.60, with a high of $101.00 and a low of $64.00. Analysts from firms like Goldman Sachs, Baird, and B of A Securities have adjusted their ratings and price targets, reflecting their views on the company's market position and recent performance. Intra-Cellular Therapies, a biopharmaceutical company, has seen a 75.05% revenue growth rate over 3 months but lags in net margin and ROE compared to industry averages.
January 18, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Intra-Cellular Therapies has received mixed analyst ratings, with an updated average price target of $81.75. The company has experienced significant revenue growth but faces challenges in profitability and returns on equity and assets.
The mixed analyst ratings and the increase in the average price target suggest a neutral short-term impact on ITCI's stock price. The substantial revenue growth is positive, but concerns about net margin, ROE, and ROA may temper investor enthusiasm. The score is neutral due to these offsetting factors.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100